InvestorsHub Logo
Followers 37
Posts 6865
Boards Moderated 1
Alias Born 09/06/2014

Re: jdlamont post# 9459

Tuesday, 10/09/2018 5:41:07 PM

Tuesday, October 09, 2018 5:41:07 PM

Post# of 15597
"GTHP light scan tech is readily adaptable and efficacious in detecting many other cancers?" What clinical trials have been done to prove this? The published proof of efficacy on Guided's website is all about the Cervix.
http://www.guidedinc.com/publications/
and their "About Us" page says this:

The platform technology that is LuViva can be applied to other forms or carcinoma. We’ve conducted human testing with the technology on patients at risk for esophageal cancer with promising results. While a great deal more testing and development work needs to be done on that product, we believe that there is a need for our technology in the esophageal market.

Other cancers, in addition to cervical and esophageal, where the technology can be applied:

Head and Neck Cancer
Anal Cancer
Colorectal Cancer
Skin Cancer


This all sounds like Safe Harbor BS to me. Where is the proof of efficacy? If this tech is efficacious for other cancers, why have they spent 20 years focusing on Cervical Cancer alone?

The HPV vaccine is very definitely "a determining factor whether this company becomes viable." It's much cheaper overall to administer a vaccine than to detect cervical cancer in women who can't afford to pay for treatment when cancer is detected.

"Vaccine penetration will be negligible especially in places like India and more in less developed countries" sounds like BS to me. Forgive the unintended pun, but Luviva Scan penetration will be FAR more negligible than HPV vaccination in places like India and in less developed countries.

Governments in Asia and Africa are simply not going to pay for enough LuViva Scans to make this company viable. If they do anything large-scale, which is debatable considering the low social status of women on these continents, they will pay for vaccinations.

Finally, regarding the statement "Pap smear testing is in the tens of billions in the U.S. by 5 big pharmas, even with Gardisil" -- Yes, the USA is a different matter. Perhaps insurance in the USA would pay for LuViva Scans. There's a problem though -- this company has placed FDA clearance on the burner located BEHIND the back burner. They haven't done ANYTHING to further FDA clearance since the third FDA rejection back in 2014.

I don't know the reason for this delay -- say it's Big Pharma interference, say it's mismanagement, say the toxic lenders are trying to starve the company into BK.... Whatever excuse we want to make, FDA clearance was, is, and always will be this company's only hope for profitability.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTHP News